Biomarker development has historically been driven by the discovery of genes involved in the regulation of key carcinogenic processes in specific tumor types (such as estrogen receptor in breast cancer, BRC-ABL in chronic myeloid leukemia, etc.)and has been tightly linked to cancer drug development. This evidence concerns the gene ESR1 and breast carcinoma.